Additional file 1: Supplementary 1. Methodology details: secondary outcomes definition, study risk of bias and confidence in the evidence assessments. Supplementary 2. Characteristics of included studies table and references. Supplementary 3. Risk of bias summary table. Supplementary 4. Table of ongoing studies (last update December 2020). Supplementary 5. Network plots of evidence for secondary outcomes. Supplementary 6. Results of the pairwise meta-analyses for primary and secondary outcomes. Supplementary 7. Assessment of the confidence in the network estimates of each drug versus placebo/no treatment and versus aspirin ≤150 mg/day by outcome. Supplementary 8. SUCRA, probability to be the best and mean rank by outcome. Supplementary 9. R...
Background: The Cerebrovascular Antiplatelet Trialists' Collaborative Group was formed to obtain and...
Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioem...
Background and Purpose— We assessed the efficacy and safety of antiplatelet agents after noncardioe...
Additional file 2. League tables from the main analysis for primary and secondary outcomes, from the...
Network meta-analysis estimates and common standard deviation heterogeneity of primary and secondary...
Background: Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke but their...
This editorial refers to ‘Network meta-analysis: simultaneous meta-analysis of common antiplatelet r...
Risk of bias assessment and references to all studies enrolled in the current meta-analysis: This ad...
we performed a systematic review and meta-analysis in order to summarize the current evidence on blo...
BACKGROUND Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke but the...
© 2015 American Heart Association, Inc. Acknowledgements C.S. Kwok and A. Shoamanesh was involved in...
Background: Antiplatelet medications such as aspirin and clopidogrel are usedfollowing thrombotic st...
OBJECTIVE: To determine the effects of antiplatelet therapy among patients at high risk of occlusive...
Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioem...
Objective To determine the effects of antiplatelet therapy among patients at high risk of occlusive ...
Background: The Cerebrovascular Antiplatelet Trialists' Collaborative Group was formed to obtain and...
Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioem...
Background and Purpose— We assessed the efficacy and safety of antiplatelet agents after noncardioe...
Additional file 2. League tables from the main analysis for primary and secondary outcomes, from the...
Network meta-analysis estimates and common standard deviation heterogeneity of primary and secondary...
Background: Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke but their...
This editorial refers to ‘Network meta-analysis: simultaneous meta-analysis of common antiplatelet r...
Risk of bias assessment and references to all studies enrolled in the current meta-analysis: This ad...
we performed a systematic review and meta-analysis in order to summarize the current evidence on blo...
BACKGROUND Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke but the...
© 2015 American Heart Association, Inc. Acknowledgements C.S. Kwok and A. Shoamanesh was involved in...
Background: Antiplatelet medications such as aspirin and clopidogrel are usedfollowing thrombotic st...
OBJECTIVE: To determine the effects of antiplatelet therapy among patients at high risk of occlusive...
Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioem...
Objective To determine the effects of antiplatelet therapy among patients at high risk of occlusive ...
Background: The Cerebrovascular Antiplatelet Trialists' Collaborative Group was formed to obtain and...
Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioem...
Background and Purpose— We assessed the efficacy and safety of antiplatelet agents after noncardioe...